A Phase 2 interventional study of Eteplirsen in Muscular Dystrophy, Duchenne, sponsored by Sarepta Therapeutics, Inc.. Completed at 9 sites in United States. Open to male participants aged 7 Years to 21 Years. Per ClinicalTrials.gov, last updated 2020-03-30.
Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 4th largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 2, and was the 6th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →
eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 7 Years to 21 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 2
First in 2007; this study’s year is marked. 2 started in 2014.
This study's enrollment of 24 is close to the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 15 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc.: 5 open now, 6 under way, 2 of them phase 3. Of 21 finished, 15 (71%) have results posted.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 13th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2014, is one of 7 in phase 2, and was the 5th registered.
Sarepta Therapeutics, Inc.’s Muscular Dystrophy, Duchenne studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, from their registry updates:
Among Sarepta Therapeutics, Inc.’s 27 in Muscular Dystrophy, Duchenne:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
This is an open-label, multi-center study to explore the safety and tolerability of eteplirsen injection in participants with advanced stage DMD with confirmed genetic mutations amenable to treatment by exon 51 skipping.
Participants will be evaluated for inclusion during a Screening/Baseline period of up to 4 weeks. Eligible participants will receive once weekly intravenous (IV) infusions of 30 mg/kg eteplirsen for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
Safety will be regularly assessed throughout the study via the collection of adverse events (AEs), laboratory tests, electrocardiograms (ECGs), echocardiograms (ECHOs), vital signs, and physical examinations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.
Drug: Eteplirsen
Eteplirsen solution for IV infusion
Also known as: AVI-4658, EXONDYS 51®
Number of Participants With Treatment Emergent Adverse Events
An adverse event (AE) was any untoward medical occurrence in a participant that did not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; Required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events that developed or worsened during the on-treatment period (defined as time from first dose of study drug and up to 28 days after last dose of study drug (up to 100 weeks) that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Time frame: From first dose of drug up to 100 weeks
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities
Laboratory parameters included hematology, clinical chemistry, urinalysis and coagulation. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal findings. Incr=increase; LLN=lower limit of normal; ULN=upper limit of normal; GGT=gamma glutamyl transferase
Time frame: Baseline up to 100 weeks
Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs
Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal vital sign findings.
Time frame: Baseline up to 100 weeks
Number of Participants With at Least One Potentially Clinically Significant Abnormalities in Physical Examinations
Physical examinations, full and brief, were performed by the Investigator, a physician Sub-Investigator, or a Nurse Practitioner (if licensed in the state or province to perform physical examinations). Full physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; skin; lymph nodes; and musculoskeletal and neurological systems. Brief physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; and skin.
Time frame: Baseline up to 100 weeks
Number of Participants With Abnormalities in Electrocardiograms (ECGs)
Twelve-lead ECGs and Holter ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the patient was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel using a central vendor according to prespecified criteria. The Investigator reviewed the results of the centrally read ECG report and determined if the findings were clinically significant. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal ECG findings. msec=milliseconds; QTcF=QT interval corrected with Fridericia's method
Time frame: Baseline up to 100 weeks
Number of Participants With Abnormalities in Echocardiograms (ECHO)
Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. The ECHO was reviewed and interpreted by medically qualified personnel using a central vendor according to prespecified criteria. Ejection fraction was noted. The Investigator reviewed the results of the ECHO report and determined if the findings were clinically significant. LEVF=left ventricular ejection fraction
Time frame: Baseline up to 100 weeks
| Milestone | Eteplirsen 30 mg/kg |
|---|---|
| Started | 24 |
| Completed | 22 |
| Not completed | 2 |
| Withdrew: Withdrawal by subject | 2 |
An adverse event (AE) was any untoward medical occurrence in a participant that did not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; Required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events that developed or worsened during the on-treatment period (defined as time from first dose of study drug and up to 28 days after last dose of study drug (up to 100 weeks) that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
| Participants | Eteplirsen 30 mg/kg |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events | 24 |
Laboratory parameters included hematology, clinical chemistry, urinalysis and coagulation. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal findings. Incr=increase; LLN=lower limit of normal; ULN=upper limit of normal; GGT=gamma glutamyl transferase
| Participants | Eteplirsen 30 mg/kg |
|---|---|
| Sodium: Decrease of 8 or more | 3 |
| Sodium: Increase of 8 or more | 3 |
| Potassium: Decrease of 1.1 or more | 2 |
| Potassium: Increase of 1.0 or more | 2 |
| Potassium: Value > 5.5 or < 3.0 | 1 |
| Calcium: Decrease of 0.30 or more | 1 |
| Glucose: Decrease of 3.1 or more | 1 |
| Glucose: Increase of 3.2 or more | 6 |
| Albumin: Value < LLN or > ULN | 4 |
| Bilirubin: Incr of 10 or more | 1 |
| Bilirubin: Value > 1.5 x ULN | 1 |
| Alanine Aminotransferase: Value >= 2 x Baseline | 1 |
| GGT: value > 3*Baseline or > ULN | 2 |
| Lactate Dehydrogenase: Value >= 2 x Baseline | 1 |
| Creatine Kinase: Value >= 2 x Baseline | 5 |
| Hemoglobin: Value < LLN | 5 |
| Hematocrit: Value < LLN | 7 |
| Red Blood Cell: Value < LLN | 4 |
| White Blood Cell: Value < LLN or > 1.5 x ULN | 5 |
| Platelets: Value < 150 or < 200 | 1 |
| Neutrophils: Value > 1.5 x ULN or < 1000 | 7 |
| Lymphocytes: Value < LLN | 6 |
| Monocytes: Value < LLN | 14 |
| Eosinophils: Value > 1.5 x ULN or < LLN | 2 |
| Basophils: Value < LLN or > ULN | 2 |
| Urine Protein: Value > 1+ | 5 |
Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal vital sign findings.
| Participants | Eteplirsen 30 mg/kg |
|---|---|
| DBP: Less than 40 mmHG | 1 |
| DBP: Greater than 90 mmHg | 12 |
| SBP: Less than 80 mmHg | 4 |
| SBP: Greater than 130 mmHG | 17 |
| HR: Less than 50 beats per minute (bpm) | 1 |
| HR: Greater than 130 bpm | 15 |
Physical examinations, full and brief, were performed by the Investigator, a physician Sub-Investigator, or a Nurse Practitioner (if licensed in the state or province to perform physical examinations). Full physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; skin; lymph nodes; and musculoskeletal and neurological systems. Brief physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; and skin.
| Participants | Eteplirsen 30 mg/kg |
|---|---|
| Number of Participants With at Least One Potentially Clinically Significant Abnormalities in Physical Examinations | 23 |
Twelve-lead ECGs and Holter ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the patient was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel using a central vendor according to prespecified criteria. The Investigator reviewed the results of the centrally read ECG report and determined if the findings were clinically significant. Data is only reported for parameters in which at least 1 participant had potentially clinically significant abnormal ECG findings. msec=milliseconds; QTcF=QT interval corrected with Fridericia's method
| Participants | Eteplirsen 30 mg/kg |
|---|---|
| Heart Rate: >120 beats/minute | 6 |
| QTcF: Increase of 60 or more msec | 1 |
Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. The ECHO was reviewed and interpreted by medically qualified personnel using a central vendor according to prespecified criteria. Ejection fraction was noted. The Investigator reviewed the results of the ECHO report and determined if the findings were clinically significant. LEVF=left ventricular ejection fraction
| Participants | Eteplirsen 30 mg/kg |
|---|---|
| LEVF: <55% | 0 |
| Fractional Shortening: <28% | 6 |
Collected over Baseline up to Week 100. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eteplirsen 30 mg/kg | 0/24 (0%) | 4/24 (16.7%) | 24/24 (100%) |
| Event | Eteplirsen 30 mg/kg |
|---|---|
| Extremity contractureMusculoskeletal and connective tissue disorders | 1/24 |
| ScoliosisMusculoskeletal and connective tissue disorders | 1/24 |
| CardiomyopathyCardiac disorders | 1/24 |
| NephrolithiasisRenal and urinary disorders | 1/24 |
| Event | Eteplirsen 30 mg/kg |
|---|---|
| NasopharyngitisInfections and infestations | 14/24 |
| Back painMusculoskeletal and connective tissue disorders | 9/24 |
| RashSkin and subcutaneous tissue disorders | 8/24 |
| HeadacheNervous system disorders | 8/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/24 |
| VomitingGastrointestinal disorders | 7/24 |
| Upper respiratory tract infectionInfections and infestations | 6/24 |
| ContusionInjury, poisoning and procedural complications | 6/24 |
| Abdominal pain upperGastrointestinal disorders | 6/24 |
| DiarrhoeaGastrointestinal disorders | 6/24 |
Safety analysis population included all enrolled participants who received at least 1 dose of eteplirsen.
| Age, Continuous(years) | Eteplirsen 30 mg/kg |
|---|---|
| Mean | 12.9 ± 3.30 |
| Sex: Female, Male(Participants) | Eteplirsen 30 mg/kg |
|---|---|
| Female | 0 |
| Male | 24 |
| Ethnicity (NIH/OMB)(Participants) | Eteplirsen 30 mg/kg |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Eteplirsen 30 mg/kg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 21 |
| More than one race | 2 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Eteplirsen 30 mg/kg |
|---|---|
| United States | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2014 to primary completion in Apr 2017, 29 months.
Results were first posted in Feb 2019, 1 year 9 months after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 29 months is close to that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eteplirsen
Muscular Dystrophy, Duchenne →